Prince William announces 15 Finalists for inaugural year of the £50 million Earthshot Prize
17.9.2021 20:01:00 EEST | Business Wire | Press release
The Earthshot Prize announces today its first-ever shortlist of 15 Finalists, each with a chance of winning £1million to support their innovative environmental solutions to the greatest challenges facing the planet.
Prince William said: "Over half a century ago, President Kennedy’s ‘Moonshot’ programme united millions of people around the goal of reaching the moon. Inspired by this, The Earthshot Prize aims to mobilise collective action around our unique ability to innovate, problem solve and repair our planet.
“I am honoured to introduce the 15 innovators, leaders, and visionaries who are the first ever Finalists for The Earthshot Prize. They are working with the urgency required in this decisive decade for life on Earth and will inspire all of us with their optimism in our ability to rise to the greatest challenges in human history.”
Launched by Prince William and The Royal Foundation in October 2020, The Earthshot Prize is the most prestigious global environment prize in history. Like President John F. Kennedy’s ‘Moonshot’ did almost 60 years ago, the Prize aims to unleash an unprecedented wave of innovation and leadership to tackle our greatest environmental challenges. The Earthshot Prize will be awarded every year for the next decade, discovering a total of 50 Winners.
Five of these 15 Finalists will be awarded The Earthshot Prize and will win £1million in Prize funding for the best solutions of the five Earthshot goals: Protect and Restore Nature; Clean our Air; Revive our Oceans; Build a Waste-free World; and Fix our Climate. The Winners will be announced during an awards ceremony on 17th October from London’s Alexandra Palace, broadcast in the UK on BBC One and globally on Discovery+.
The Earthshot Prize Finalists for 2021 are:
Protect and Restore Nature:
- Pole Pole Foundation, Democratic Republic of Congo
An inspiring community-led model of conservation that protects gorillas and local livelihoods.
- The Republic of Costa Rica
A pioneering scheme paying local citizens to restore natural ecosystems that has led to a revival of the rainforest.
- Restor, Switzerland
A ground-breaking online platform connecting and empowering local conservation projects.
Clean our Air:
- The Blue Map App, China
China’s first public environmental database enabling citizens to hold polluters to account.
- Takachar, India
A pioneering technology to create profitable products from agricultural waste and put a stop to the burning of crops.
- Vinisha Umashankar, India
A 14-year-old innovator and activist who has designed a solar-powered ironing cart with the potential to improve air quality across India.
Revive our Oceans:
- Coral Vita, Bahamas
A truly cutting-edge breakthrough in coral farming that can restore our world’s dying coral reefs.
- Living Seawalls, Australia
Innovative and replicable seawall panels bringing marine life back to coastal sea defences.
- Pristine Seas, USA
An unprecedented global conservation programme protecting 6.5 million square km of the world’s ocean.
Build a Waste-Free World:
- The City of Milan Food Waste Hubs, Italy
A city-wide initiative that has dramatically cut waste while tackling hunger.
- Sanergy, Kenya
A circular sanitation solution that converts human waste into safe products for local farmers.
- WOTA BOX, Japan
A tiny water treatment plant that turns 98% of wastewater into clean water.
Fix our Climate:
- AEM Electrolyser, Thailand/Germany/Italy
An ingenious green hydrogen technology developed to transform how we power our homes and buildings.
- Reeddi Capsules, Nigeria
Solar-powered energy capsules making electricity affordable and accessible in energy-poor communities.
- SOLbazaar, Bangladesh
The world’s first peer-to-peer energy exchange network in a country on the front-line of climate change.
All 15 Finalists will receive support from The Earthshot Prize Global Alliance Members, an unprecedented network of global businesses, who will help scale their solutions for even greater impact.
Of these 15 Finalists, the five Winners will be selected by The Earthshot Prize Council, a diverse team of influential individuals which includes: HRH Prince William, Her Majesty Queen Rania Al Abdullah of Jordan, Sir David Attenborough, Dr Ngozi Okonjo-Iweala, Indra Nooyi, Shakira Mebarak, Christiana Figueres, Luisa Neubauer, Cate Blanchett, Yao Ming, Daniel Alves Da Silva, Ernest Gibson, Hindou Oumarou Ibrahim, Jack Ma, and Naoko Yamazaki.
In the run-up to the prize-giving ceremony on 17 October, BBC and Discovery will release a 5-part documentary series THE EARTHSHOT PRIZE: REPAIRING OUR PLANET, featuring Earthshot Prize Council Members including Prince William, Shakira Mebarak, Daniel Alves Da Silva and Sir David Attenborough.
For more information about the Finalists and The Earthshot Prize, visit: www.earthshotprize.org, email Claire Straw: TEPmedia@freuds.com, download media pack here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210917005454/en/
Contact information
Claire Straw:
TEPmedia@freuds.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom